Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Fennec Pharmaceuticals (FENC) stock in plain English

Free brief · no signupStart here
FENCPublished Nov 18, 2026
Fennec Pharmaceuticals Inc
Healthcare · Biotechnology
Sells an intravenous formulation of sodium thiosulfate to protect children from cisplatin chemotherapy side effects.
Assets:
Pedmark product lineApproved prescription therapy used across United States pediatric cancer centers
Pedmarqsi European approvalCommercial authorization granted by the European Commission for pediatric cancer patients
Third-party manufacturing networkOutsources drug substance formulation and vial filling entirely to specialized contract partners
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

67
OPS ScoreOperating finances
Latest quote
+0.90%$13.45
$474.86M
805.4×
$66.41M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was FENC. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Fennec Pharmaceuticals (FENC) do?

Fennec Pharmaceuticals Inc (FENC) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells an intravenous formulation of sodium thiosulfate to protect children from cisplatin chemotherapy side effects. It sells the only approved therapy specifically designed to prevent chemotherapy-induced hearing loss in pediatric. It is worth $474.86M on the market and sold $66.41M over the last year.

Market cap
$474.86M
P/E ratio
805.4×
Annual sales
$66.41M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 18, 2026

Brands and businesses behind FENC

  • Pedmark: An injectable drug prescribed to reduce hearing loss in pediatric chemotherapy patients, generating revenue from direct hospital sales.
  • Pedmarqsi: The European brand of sodium thiosulfate sold to healthcare providers to protect pediatric oncology patients from ototoxicity.

FENC’s flags, in plain English

Each flag is a number from Fennec Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Stupid Cash

Can pay this year's bills 6.1 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 0% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 94.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Priced for Perfection

Priced at 805.4 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about FENC

How big is Fennec Pharmaceuticals?

Fennec Pharmaceuticals’ market cap is $474.86M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $66.41M: what customers paid the company over the last year, before any costs.

What is FENC’s P/E ratio?

FENC’s P/E ratio is 805.4×. Investors pay about 805.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with FENC?

The business relies entirely on a single drug for all of its revenue, leaving it exposed if prescribing rates drop. That is one risk on Fennec Pharmaceuticals’ card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Fennec Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. FENC’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card